Measles, mumps, rubella (MMR) *,7 Pneumococcal 13-valent conjugate (PCV13) *,8 Pneumococcal polysaccharide (PPSV23) 8
Hepatitis A *,9
Hepatitis B *,10 Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4) *,11 Meningococcal B (MenB) 11 Haemophilus influenzae type b (Hib) *,12 These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults aged ≥19 years, as of February 2016. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the 
dose 3 doses post-HSCT recipients only
Recommended for all persons who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection; zoster vaccine is recommended regardless of past episode of zoster 
Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
• Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy (preferably during 27-36 weeks' gestation) regardless of interval since prior Td or Tdap vaccination. • Persons aged ≥11 years who have not received Tdap vaccine or for whom vaccine status is unknown should receive a dose of Tdap followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be administered regardless of interval since the most recent tetanus or diphtheriatoxoid-containing vaccine. • Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose. • For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6-12 months after the second. • For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses. • Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote 1).
Varicella vaccination
• All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose. • Vaccination should be emphasized for those who have close contact with persons at high risk for severe disease (e.g., health care personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers). • Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the health care facility. The second dose should be administered 4-8 weeks after the first dose. • Evidence of immunity to varicella in adults includes any of the following: -documentation of 2 doses of varicella vaccine at least 4 weeks apart; -U.S.-born before 1980, except health care personnel and pregnant women; -history of varicella based on diagnosis or verification of varicella disease by a health care provider; -history of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider; or laboratory evidence of immunity or laboratory confirmation of disease.
Human papillomavirus (HPV) vaccination
• Three HPV vaccines are licensed for use in females (bivalent HPV vaccine [2vHPV], quadrivalent HPV vaccine [4vHPV], and 9-valent HPV vaccine [9vHPV]) and two HPV vaccines are licensed for use in males (4vHPV and 9vHPV). • For females, 2vHPV, 4vHPV, or 9vHPV is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not previously vaccinated. • For males, 4vHPV or 9vHPV is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 21 years, if not previously vaccinated. Males aged 22 through 26 years may be vaccinated. • HPV vaccination is recommended for men who have sex with men through age 26 years who did not get any or all doses when they were younger. • Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years who did not get any or all doses when they were younger. • A complete HPV vaccination series consists of 3 doses. The second dose should be administered 4-8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administered 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).
• HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion or termination of pregnancy.
Zoster vaccination
• A single dose of zoster vaccine is recommended for adults aged ≥60 years regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged ≥50 years, ACIP recommends that vaccination begin at age 60 years. • Persons aged ≥60 years with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.
Measles, mumps, rubella (MMR) vaccination
• Adults born before 1957 are generally considered immune to measles and mumps.
All adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine or laboratory evidence of immunity to each of the three diseases. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella. Alaska Native or other adults unless they have an indication as above; however, public health authorities may consider recommending the use of pneumococcal vaccines for American Indians/Alaska Natives or other adults who live in areas with increased risk for invasive pneumococcal disease.
Hepatitis A vaccination • Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:
men who have sex with men; -persons who use injection or noninjection illicit drugs; -persons working with HAV-infected primates or with HAV in a research laboratory setting; -persons with chronic liver disease and persons who receive clotting factor concentrates; -persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (see footnote 1); and unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity of hepatitis A (see footnote 1). The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee. • Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6-12 months (Havrix), or 0 and 6-18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21-30 followed by a booster dose at 12 months.
Hepatitis B vaccination • Vaccinate any person seeking protection from hepatitis B virus (HBV) infection and persons with any of the following indications:
sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection drug users; and men who have sex with men; -health care personnel and public safety workers who are potentially exposed to blood or other infectious body fluids; -persons who are aged <60 years with diabetes as soon as feasible after diagnosis; persons with diabetes who are aged ≥60 years at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination; -persons with end-stage renal disease (including patients receiving hemodialysis), persons with HIV infection, and persons with chronic liver disease; -household contacts and sex partners of hepatitis B surface antigenpositive persons, clients and staff members of institutions for persons with developmental disabilities, and international travelers to regions with high or intermediate levels of endemic HBV infection (see footnote 1); and all adults in the following settings: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, health care settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities. • Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered at least 1 month after the first dose; the third dose should be administered at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule may be used, administered on days 0, 7, and 21-30, followed by a booster dose at 12 months. • Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.
Meningococcal vaccination
• General information -Serogroup A, C, W, and Y meningococcal vaccine is available as a conjugate (MenACWY [Menactra, Menveo]) or a polysaccharide (MPSV4 [Menomune]) vaccine. -Serogroup B meningococcal (MenB) vaccine is available as a 2-dose series of MenB-4C vaccine (Bexsero) administered at least 1 month apart or a 3-dose series of MenB-FHbp (Trumenba) vaccine administered at 0, 2, and 6 months; the two MenB vaccines are not interchangeable, i.e., the same MenB vaccine product must be used for all doses. -MenACWY vaccine is preferred for adults with serogroup A, C, W, and Y meningococcal vaccine indications who are aged ≤55 years, and for adults aged ≥56 years: 1) who were vaccinated previously with MenACWY vaccine and are recommended for revaccination or 2) for whom multiple doses of vaccine are anticipated; MPSV4 vaccine is preferred for adults aged ≥56 years who have not received MenACWY vaccine previously and who require a single dose only (e.g., persons at risk because of an outbreak). -Revaccination with MenACWY vaccine every 5 years is recommended for adults previously vaccinated with MenACWY or MPSV4 vaccine who remain at increased risk for infection (e.g., adults with anatomical or functional asplenia or persistent complement component deficiencies, or microbiologists who are routinely exposed to isolates of Neisseria meningitidis). 
Haemophilus influenzae type b (Hib) vaccination
• • Moderate or severe acute illness with or without fever • Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination Measles, mumps, rubella (MMR) 3 • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy, 4 or patients with HIV infection who are severely immunocompromised) • Pregnancy • Moderate or severe acute illness with or without fever • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product) 5 • History of thrombocytopenia or thrombocytopenic purpura • Need for tuberculin skin testing 6 Pneumococcal conjugate (PCV13) • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including to any vaccine containing diphtheria toxoid • Moderate or severe acute illness with or without fever Pneumococcal polysaccharide (PPSV23)
• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component 
